BD Begins Clinical Trial for GalaFLEX LITE Scaffold in Breast Revision Surgery
BD begins a clinical trial to evaluate GalaFLEX LITE Scaffold for reducing capsular contracture in breast revision surgery, aiming for FDA approval.
BD begins a clinical trial to evaluate GalaFLEX LITE Scaffold for reducing capsular contracture in breast revision surgery, aiming for FDA approval.
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.